VINCRISTINE-TEVA

Active material: Vynkrystyn
When ATH: L01CA02
CCF: Anticancer drug
When CSF: 22.03.01
Manufacturer: TEVA Pharmaceutical Industries Ltd. (Israel)

Pharmaceutical form, composition and packaging

Solution Injectable clear, a colorless or slightly yellow, free of mechanical impurities.

Excipients: mannitol, metilgidroksiʙenzoat, propyl, Sodium hydroxide, sulfuric acid, water d / and.

1 ml – vials of dark glass (1) – packs cardboard.

Solution for injection clear, a colorless or slightly yellow, free of mechanical impurities.

Excipients: mannitol, metilgidroksiʙenzoat, propyl, Sodium hydroxide, sulfuric acid, water d / and.

2 ml – vials of dark glass (1) – packs cardboard.

Solution for injection clear, a colorless or slightly yellow, free of mechanical impurities.

[Ring] mannitol, metilgidroksiʙenzoat, propyl, Sodium hydroxide, sulfuric acid, water d / and.

5 ml – vials of dark glass (1) – packs cardboard.

DESCRIPTION OF ACTIVE SUBSTANCES.

Pharmacological action

The antitumor agent. The mechanism of action is related to the blockade of tubulin and stopping cell division in metafaze.

Pharmacokinetics

GEB in small quantities. Plasma protein binding – about 75%. Biotransformed in the liver. Report mostly in the form of metabolites, the bile (about 67%) and kidneys (about 12%).

Testimony

Acute leukemia, limfogranulematoz, non-Hodgkin's lymphoma, multiple myeloma, raʙdomiosarkoma, sarkoma Juinga, bone and soft tissue sarcoma, osteosarcoma, sympathicoblastoma, Kaposi's sarcoma, uterine sarcoma, mammary cancer, small cell lung cancer, melanoma, epitheliomatous ulceration, cancer of the renal pelvis and ureter, bladder cancer, Wilms' tumor, cervical cancer, testicular germ cell tumors and ovarian cancer, choriocarcinoma of the uterus, ependymoma, meningoblastoma, pleurisy tumor etiology, genital cancers in girls. Idiopaticheskaya trombotsitopenicheskaya purpura (When resistance to the SCS and inefficiency splenektomii).

Dosage regimen

Establish individually, depending on the evidence and disease stage, the state of the hematopoietic system, scheme anticancer therapy.

Side effect

From the hematopoietic system: leukopenia, anemia, thrombocytopenia.

From the central and peripheral nervous system: Neuropathy, Neuritis of peripheral nerves, headache, convulsions, ataxia, depression, diplopia, ptosis, hallucinations, sleep disorders.

From the urinary system: polyuria, dizurija, atonic bladder, swelling, ostraya mochekislaya nephropathy.

From the digestive system: vomiting, diarrhea, stomatitis, constipation, anorexia, paralytic ileus (especially common in children).

Other: alopecia (following the withdrawal of treatment), hypotension, swelling.

Contraindications

Central and peripheral nervous system diseases, severe leukopenia, pregnancy.

Pregnancy and lactation

Vincristine is contraindicated for use in pregnancy. If necessary, use during lactation should stop breastfeeding.

Women of childbearing age, receiving vincristine, must use reliable methods of contraception.

IN experimental studies teratogenic and fetotoxic effect of vincristin.

Cautions

Do not recommend the use of vincristine in patients with chicken pox (incl. recently transferred or after contact with sick), with herpes zoster, other acute infectious diseases.

Use caution when applying vinchristina gout (incl. history) and nefrolitiaze, and in patients, previously treated with cytotoxic or radiation therapy.

The frequency of side effects vinchristina is related to the total dose and duration of therapy.

While the radiation therapy to the area of the spinal cord may increase neurotoxic actions of vincristin.

Neirotoksicskih effects risk higher in elderly patients and those with neurological diseases in history. With the development of peripheral neuritis should stop introduction of vincristin.

The treatment must be monitored picture peripheral blood, activity liver transaminaz and LDG, concentrations of uric acid and bilirubin in blood plasma.

During treatment is not recommended vaccination of patients and their families.

Be wary appoint the drug together with the use of medicines, inhibiting CYP3A CYP.

IN experimental studies found carcinogenic and mutagenic effect of vincristin.

Drug Interactions

While applying vincristine enhances neurotoxic effects of other drugs.

While applying vincristine ters protivopodagricakih preparations. Together with the application urikozuricescimi means increased risk of nephropathy.

Introduction to the use of bleomycin vinchristina enhances Antitumor effect of therapy.

The combined application with mitomycine c can cause respiratory depression, bronchospasm, especially in predisposed patients.

While applying vinchristina and itraconazole may earlier and heavier development of neurotoxic effect.